跳至主要内容
临床试验/NCT01966497
NCT01966497Unknown不适用

Observational Study of Patients Older Than 60 Years and With Acute Myeloblastic Leukemia Who Are Administered Standard Chemotherapy Based on Idarubicine-cytarabine

Assistance Publique - Hôpitaux de Paris1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2012年11月最近更新:
适应症

试验速览

阶段
不适用
入组人数
1,000
试验地点
1
主要终点
cumulative incidence of failures

研究概览

简要总结

The main objective of this observational survey is to estimate the incidence, the typology, and the evolution of patients with acute myelobalstic leukemia, aged more than 60 years old. In this age group (aged more than 60y), three groups of patients with very different response rates and late outcome can be delineated with specific standard chemotherapy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 60 years or more
  • With a morphologically proven diagnosis of AML according to WHO 2008 classification
  • Not previously treated for AML
  • Signed informed consent.

排除标准

  • APL in the WHO classification.
  • Ph1-positive AML or prior Ph1-positive disease
  • AML evolving from a prior MPN in the WHO 2008 classification.
  • Prior tumor, if not stable for at least two years, except in-situ carcinoma and skin carcinoma
  • ECOG Performance Status Score > 3
  • Positive serology for HIV or HTLV1, or active viralinfection for HBV and HBC.
  • Severe uncontrolled infection at inclusion time.
  • Psychiatric disease or an history of non-complianceto medical regimens or patients considered potentially unreliable.
  • Absence of Health Care Insurance

结局指标

主要结局

cumulative incidence of failures

时间窗: 9 months

failures include * resistant disease defined according to the IWG AML response criteria * hypoplastic marrow after D42 and absence of myeloidrecovery * early relapse up to 9 months from CR : Either AML relapse as in the IWG classification or MDS relapse

次要结局

  • response rate(9 months)
  • relapse rate(within 2 years after inclusion)
  • overall survival(within 2 years after inclusion)
  • adverse events(within 2 years after inclusion)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Observational Study of Patients Older Than 60 Years... | 临床试验